• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    GRI Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/15/25 8:35:54 AM ET
    $GRI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRI alert in real time by email
    val-20250515
    FALSE000182429300018242932025-05-152025-05-15

    Image_0.jpg

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549 FORM 8-K

    CURRENT REPORT
    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): May 15, 2025
    Image_8.jpg
    GRI BIO, INC.
    (Exact name of registrant as specified in its charter)
    Delaware001-4003482-4369909
    (State or other jurisdiction(Commission File Number)(IRS Employer Identification No.)
    of incorporation)
    2223 Avenida de la Playa, Suite 208
    La Jolla, CA 92037
    (Address of principal executive offices and zip code)
    (619) 400-1170
    (Registrant’s telephone number, including area code)
    N/A
    (Former name or former address, if changed since last report)
    Image_8.jpg
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Stock, par value $0.0001 per share
    GRI
    The Nasdaq Capital Market
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
    Emerging Growth Company ☒
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
    Image_0.jpg

    Image_8.jpg




    Item 2.02 Results of Operations and Financial Condition.
    On May 15, 2025, GRI Bio, Inc. (the Company) issued a press release announcing its financial results for the three months ended March 31, 2025, and provided a business update. A copy of this press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.
    The information in this report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying Exhibit 99.1 shall not be deemed incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof regardless of any general incorporation language in such filing.

    Item 9.01 Financial Statements and Exhibits.
    (d) Exhibits
    Exhibit No. Description
    99.1
    Press Release issued by GRI Bio, Inc., dated May 15, 2025.
    104Cover Page Interactive Data File (embedded within the Inline XBRL document).



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    Date: May 15, 2025GRI Bio, Inc.
    By: /s/ Leanne Kelly
    Leanne Kelly
    Chief Financial Officer



    Get the next $GRI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRI

    DatePrice TargetRatingAnalyst
    12/9/2024$10.00Buy
    H.C. Wainwright
    More analyst ratings

    $GRI
    SEC Filings

    See more
    • GRI Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - GRI Bio, Inc. (0001824293) (Filer)

      5/23/25 7:16:47 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by GRI Bio Inc.

      424B5 - GRI Bio, Inc. (0001824293) (Filer)

      5/23/25 7:14:51 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by GRI Bio Inc.

      10-Q - GRI Bio, Inc. (0001824293) (Filer)

      5/15/25 8:38:34 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRI
    Leadership Updates

    Live Leadership Updates

    See more
    • Connect Biopharma Announces New Leadership and Chair of the Board of Directors

      Industry leader Barry Quart, Pharm.D. appointed as Chief Executive Officer succeeding Zheng Wei, Ph.D., who will remain on the Board of Directors and serve as an advisor to assist with the transitionExperienced life science executive David Szekeres appointed as PresidentKleanthis G. Xanthopoulos, Ph.D. appointed as Chair of the Board of Directors SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cel

      6/12/24 4:15:00 PM ET
      $CNTB
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GRI Bio (NASDAQ: GRI) Announces Appointment of Leanne Kelly as Chief Financial Officer

      - Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm LA JOLLA, CA, April 25, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the appointment of Leanne Kelly as its Chief Financial Officer. Ms. Kelly is an accomplished financial executive with over 20 years of experience leading private and publicly traded companies across life science, technology and e-Commerce

      4/25/23 8:45:00 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Kelly Leanne

      4 - GRI Bio, Inc. (0001824293) (Issuer)

      1/24/25 5:58:28 PM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Chaturvedi Vipin

      4 - GRI Bio, Inc. (0001824293) (Issuer)

      1/24/25 5:58:17 PM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Hertz Walter Marc

      4 - GRI Bio, Inc. (0001824293) (Issuer)

      1/24/25 5:58:06 PM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on GRI Bio with a new price target

      H.C. Wainwright initiated coverage of GRI Bio with a rating of Buy and set a new price target of $10.00

      12/9/24 7:50:37 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results

      Data presented at the 2025 American Thoracic Society (ATS) International Conference Pre-clinical and interim clinical results underscore GRI-0621's potential to have both anti-inflammatory and anti-fibrotic effects in pulmonary fibrosis Results from 6-week interim analysis (n=24) in ongoing Phase 2a study of GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) anticipated in Q2 2025 LA JOLLA, CA, May 22, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the pr

      5/22/25 8:00:00 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GRI Bio to Participate in the Virtual Investor Closing Bell Series

      Live webcast on Wednesday, May 28th at 4:00 PM ET LA JOLLA, CA, May 21, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will participate in the Virtual Investor Closing Bell Series on Wednesday, May 28, 2025 at 4:00 PM ET. As part of the event, Dr. Hertz will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submi

      5/21/25 9:15:00 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

      Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer on Wednesday, May 21st at 2:40 PM ET LA JOLLA, CA, May 16, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase being held virtually on Wednesday, May 21, 2025 at 2:40 PM ET. Click here to register for the event. A live webcast of the fireside chat will be accessible

      5/16/25 9:15:00 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care